As of 2025-10-14, the Intrinsic Value of ImmuPharma PLC (IMM.L) is -8.79 GBP. This IMM.L valuation is based on the model Peter Lynch Fair Value. With the current market price of 11.10 GBP, the upside of ImmuPharma PLC is -179.18%.
Based on its market price of 11.10 GBP and our intrinsic valuation, ImmuPharma PLC (IMM.L) is overvalued by 179.18%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -8.79 - -8.79 | -8.79 | -179.18% |
| P/E | (10.66) - (13.99) | (12.69) | -214.3% |
| DDM - Stable | (4.03) - (10.40) | (7.21) | -165.0% |
| DDM - Multi | (2.15) - (4.47) | (2.92) | -126.3% |
| Market Cap (mil) | 60.33 |
| Beta | 0.99 |
| Outstanding shares (mil) | 5.43 |
| Enterprise Value (mil) | 59.93 |
| Market risk premium | 5.98% |
| Cost of Equity | 13.44% |
| Cost of Debt | 5.00% |
| WACC | 8.94% |